FROM SARALASIN TO SARTANS: HISTORY OF THE ANGIOTENSIN II RECEPTOR BLOCKADE


Цитировать

Полный текст

Аннотация

Представлены история создания блокаторов рецепторов ангиотензина II и опыт их применения в контролируемых клинических исследованиях

Об авторах

В В Фомин

Кафедра терапии и профболезней ММА им. И.М. Сеченова

Кафедра терапии и профболезней ММА им. И.М. Сеченова

М М Курашов

Кафедра терапии и профболезней ММА им. И.М. Сеченова

Кафедра терапии и профболезней ММА им. И.М. Сеченова

V Fomin

M Kurashov

Список литературы

  1. Basso N., Terragno N.A. History about the discovery of renin-angiotensin system. Hypertension 2001; 38: 1246-1249.
  2. Braun-Menendez E., Fasciolo J.C., Leloir L.F. et al. The substance causing renal hypertension. J. Physiol. 1940; 98: 283-298.
  3. Page I.H., Helmer О.H. A crystalline pressor substance (angiotonin) resulting from the interaction between renin and renin activator. J. Exp. Med. 1940; 71: 29-42.
  4. Braun-Menendez E., Page I.H. Suggested revision of nomenclature: angiotensin. Science. 1958; 127:242.
  5. Ferreira S.H. A bradykinin-potentiating factor (BPF) present in venom of Bothrops jararaca. Br. J. Pharmacol. 1965; 24: 163-169.
  6. Ondetti M.A., Rubin B., Cushman D.W. Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents. Science. 1977; 196(4288): 441-444.
  7. Pals D.T., Masucci F.D., Sipos F. A specific competitive antagonist of the vascular action of angiotensin II. Circ. Res. 1971; 29: 664-672.
  8. Castellion A.W., Fulton R.W. Preclinical pharmacology of saralasin. Kidney Int. 1979 (9 Suppl.): S11-S19.
  9. Brunner H.R., Laragh J.H., Baer L. et al. Essential hypertension: renin and aldosterone, heart attack and stroke. N. Engl. J. Med. 1972; 286(9): 441-449.
  10. Gavras H., Gavras I., Brunner H.R. et al. Physiologic studies with saralasin in animals. Kidney Int. 1979; (9 Suppl.): S20-S28.
  11. Steiner R.W., Blantz R.C. Acute reversal by saralasin of multiple intrarenal effects of angiotensin II. Am. J. Physiol. 1979; 237(5): F386-F391.
  12. Miller E.D., Delaney T.J. Blood flow alteration induced by saralasin or sodium nitroprusside in rats. Anestesiology 1981; 54(3): 199-203.
  13. Delaney T.J., Miller E.D. Rebound hypertensive after sodium nitroprusside prevented by saralasin in rats. Anestesiology 1980; 52(2): 154-156.
  14. Anderson D.F., Binder N.D. Short-term saralasine blockade of renal hypertension in fetal lambs. J. Physiol. 1991; 433: 383-392
  15. Ribout C., Yamaguchi N., Godin D. et al. Intracoronary administration of saralasin: effects on cardiac arrhythmias induced by ischemia and reperfusion in the anaesthetized dog. Cardiovasc. Res. 1992; 26(10): 968-972.
  16. Streeten D.H., Anderson G.H., Freiberg J.M. et al. Use of an angiotensin II antagonist (saralasin) in the recognition of "angiotensinogenic" hypertension. N. Engl. J. Med. 1975; 292(13): 657-662.
  17. Case D.B., Wallace J.M., Keim H.J. et al. Usefulness and limitations of saralasin, a partial competetitive agonist of angiotensinogen II, for evaluating the renin and sodium factors in hypertensive patients. Am. J. Med. 1976; 60(6): 825-836.
  18. Konrads A., Meurer K.A., Hummerich W. et al. Antihypertensive effects of captopril and saralasin in essential hypertension. Am. J. Cardiol. 1982; 49(6): 1558-1560.
  19. Huland H., Bause H.W., Clausen C. et al. The influence of an angiotensin II antagonist, saralasin, given before nephrectomy, on kidney function after transplantation. A contolled prospective study. Transplantation 1983; 36(2): 139-142.
  20. Symons J.D., Stebbins C.L. Effects of angiotensin II receptor blockade during exercise: comparison of losartan and saralasin. J. Cardiovasc. Pharmacol. 1996; 28(2): 223-231.
  21. Ip S.P., Tsang S.W., Wong T.P. et al. Saralasin, a nonspecific angiotensin II receptor antagonist, attenuates oxidative stress and tissue injury in cerulein-induced acute pancreatitis. Pancreas 2003; 26(3): 224-229.
  22. Burnier M., Brunner H.R. Angiotensin II receptor antagonists. Lancet 2000; 355: 637-645.
  23. Pitt B., Poole-Wilson P.A., Segal R. et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial - The Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582-1587.
  24. Julius S., Kjeldsen S.E., Weber M. et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022-2031.
  25. Dickstein K., Kjekshus J.; OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet. 2002; 360(9335): 752-760.
  26. Dahlof B., Devereux R.B., Kjeldsen S.E., LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
  27. Lindholm L.H., Carlberg B., Samuelsson O. Should beta-blockers remain first-choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366: 1545-1553.
  28. Ogihara T., Fujimoto A., Nakao K., Saruta T.; CASE-J Trial Group. ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial. Expert. Rev. Cardiovasc. Ther. 2008; 6(9): 1195-1201.
  29. Lindholm L., Ibsen H., Dahlof B. et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertenstion study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004-1010.
  30. Malmqvist K., Kahan T., Edner M., et al. Comparison of actions of irbesartan versus atenolol on cardiac repolarization in hypertensive left ventricular hypertrophy: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation Versus Atenolol (SILVHIA). Am. J. Cardiol. 2002; 90(10): 1107-1112.
  31. Mortsell D., Malmqvist K., Held C., et al. Irbesartan reduces common carotid artery intima-media thickness in hypertensive patients when compared with atenolol: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) study. J. Intern. Med. 2007; 261(5): 472-479.
  32. Комитет экспертов Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов. Диагностика и лечение артериальной гипертонии. Российские рекомендации (третий пересмотр). М., 2008.
  33. Parving H-H., Lehnert H., Brochner-Mortensen J. et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N. Engl. J. Med. 2001; 345: 870-878.
  34. Persson F., Rossing P., Hovind P. et al. Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudy. Diabetes. 2006; 55(12): 3550-3555.
  35. Llewelyn D.E., Garcia-Puig J. How different urinary albumin excretion rates can predict progression to nephropathy and the effect of treatment in hypertensive diabetics. J. Renin Angiotensin Aldosterone Syst. 2004; 5(3): 141-145.
  36. Rossing K., Christensen P.K., Andersen S. et al. Comparative effects of Irbesartan on ambulatory and office blood pressure: a substudy of ambulatory blood pressure from the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria study. Diabetes Care. 2003; 26(3): 569-574.
  37. Andersen S., Brochner-Mortensen J., Parving H.H.; Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria Study Group. Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria. Diabetes Care. 2003; 26(12): 3296-3302.
  38. Palmer A.J., Annemans L., Roze S. et al. Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease. Diabetes Care. 2004; 27(8): 1897-1903.
  39. Macfarlane D.P., Paterson K.R., Fisher M. Cardiovascular drugs as antidiabetic agents: evidence for prevention of type 2 diabetes. Diabetes Obes. Metab. 2008; 10(7): 533-544.
  40. Ernsberger P., Koletsky R.J. Metabolic actions of angiotensin receptor antagonists: PPAR-gamma agonist actions or a class effect? Curr. Opin. Pharmacol. 2007; 7(2): 140-145.
  41. Чазова И.Е., Мычка В.Б. Метаболический синдром. М., 2004.
  42. Мычка В.Б., Мамырбаева К.М., Масенко В.П. и др. Возможности антигипертензивной терапии ирбесартаном в коррекции инсулинорезистентности и нарушений мозгового кровотока у больных с метаболическим синдромом // Сonsilium Medicum. 2006. Т. 8. № 11. С. 25-30.
  43. Kintscher U., Bramlage P., Paar W.D. et al. Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients. Cardiovasc. Diabetol. 2007; 6: 12.
  44. Clasen R., Schupp M., Foryst-Ludwig A. et al. PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension. 2005; 46(1): 137-143.
  45. Di Filippo C., Lampa E., Tufariello E. et al. Effects of irbesartan on the growth and differentiation of adipocytes in obese zucker rats. Obes. Res. 2005; 13(11): 1909-1914
  46. Voigt J.P., Bramlage P., Fink H. Hypophagic effect of the angiotensin AT(1) receptor antagonist irbesartan in rats. Eur. J. Pharmacol. 2007; 535: 233-237.
  47. de las Heras N., Martin-Fernandez B., Miana M. et al. The protective effect of irbesartan in rats fed a high fat diet is associated with modification of leptin-adiponectin imbalance. J. Hypertens. 2009; 27 (Suppl. 6): S37-S41.
  48. Anand K., Mooss A.N., Hee T.T., Mohiuddin S.M. Meta-analysis: inhibition of renin-angiotensin system prevents new-onset atrial fibrillation. Am. Heart J. 2006; 152(2): 217-222.
  49. Ehrlich J.R., Nattel S. Novel approaches for pharmacological management of atrial fibrillation. Drugs. 2009; 69(7): 757-774.
  50. Madrid A.H., Bueno M.G., Rebollo J.M.G. et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation. 2002; 106: 331-336.
  51. Massie B.M., Carson P.E., McMurray J.J. et al. I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. N. Engl. J. Med. 2008; 359: 2456-2467.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах